Technical Analysis for KMDA - Kamada Ltd.

Grade Last Price % Change Price Change
grade B 5.92 -0.67% -0.04
KMDA closed down 0.67 percent on Friday, November 15, 2019, on 4.31 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical KMDA trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
New Uptrend Bullish 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Pocket Pivot Bullish Swing Setup -0.67%
Volume Surge Other -0.67%

Older signals for KMDA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kamada Ltd., a biopharmaceutical company, develops, produces, and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases; Heparin Lock Flush to maintain potency of intravenous injection device; Kamacaine 0.5%, a spinal and epidural anesthesia; and Albumin for therapeutic plasma exchange and hypovolemic shock. In addition, the company offers Factor IX for treatment of bleeding episodes and to maintain plasma factor IX levels; Factor VIII, VWF for the treatment of bleeding episodes to maintain plasma factor VIII level, vonwillebrand disease; and Human Transferrin for in vitro and diagnostic use. Its development stage products include Aerosolized AAT, which is in Phases II-III clinical trials for alpha-1 antitrypsin deficiency, and under Phase II clinical trial for bronchiectasis, as well as completed Phase II clinical trial for cystic fibrosis; Human Transferrin for pharmaceutical use; and snake antiserum for snake bites. The company has a collaboration partnership with PARI for the development of an aerosolized AAT treatment. Kamada Ltd. sells its products through distributors worldwide, as well as is involved in marketing of imported complementing products in Israel. The company was founded in 1990 and is headquartered in Ness Ziona, Israel.
Medicine Biopharmaceutical Anatomy Cystic Fibrosis Blood Cardiac Surgery Antitrypsin Deficiency Blood Products Coagulation System Coagulation Alpha 1 Antitrypsin Bronchiectasis Heparins Immune Thrombocytopenic Purpura
Is KMDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.7
52 Week Low 4.63
Average Volume 24,551
200-Day Moving Average 5.5939
50-Day Moving Average 5.2244
20-Day Moving Average 5.3239
10-Day Moving Average 5.472
Average True Range 0.1487
ADX 27.19
+DI 42.6155
-DI 7.6295
Chandelier Exit (Long, 3 ATRs ) 5.6539
Chandelier Exit (Short, 3 ATRs ) 5.5061
Upper Bollinger Band 5.8177
Lower Bollinger Band 4.8301
Percent B (%b) 1.1
BandWidth 18.550311
MACD Line 0.1497
MACD Signal Line 0.0665
MACD Histogram 0.0832
Fundamentals Value
Market Cap 221.41 Million
Num Shares 37.4 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -118.40
Price-to-Sales 2.15
Price-to-Book 2.76
PEG Ratio 9.35
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.22
Resistance 3 (R3) 6.25 6.17 6.17
Resistance 2 (R2) 6.17 6.10 6.16 6.15
Resistance 1 (R1) 6.05 6.05 6.01 6.02 6.14
Pivot Point 5.97 5.97 5.96 5.96 5.97
Support 1 (S1) 5.85 5.90 5.81 5.82 5.70
Support 2 (S2) 5.77 5.85 5.76 5.69
Support 3 (S3) 5.65 5.77 5.67
Support 4 (S4) 5.62